Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Flisom Raises Funding to Ramp Up 15 MW Flexible CIGS Production Plant

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Flisom closes 3rd funding round and signs R&D collaboration agreement with Empa.

Flisom has raised a substantially large investment to further develop its technology and build a production plant with an annual capacity of 15MW in Switzerland.

Besides securing financial backing, Flisom also signed an agreement with Empa, the Swiss Federal Laboratories for Materials Science and Technology, to provide research and development support on high-efficiency flexible CIGS solar cell technology.

Flisom’s third funding round was completed with participation from a Swiss investor along with Flisom’s existing strategic investor, Tata, India’s largest and most respected business house.

“This new investment marks investors’ satisfaction with Flisom’s progress towards the development of industrial manufacturing technology for roll-to-roll production of flexible solar modules. The 15MW plant will serve as a blueprint towards the establishment of larger-scale plants to manufacture flexible solar modules at low cost”, says Flisom’s interim CEO Marc Kaelin. “Flisom’s technology shows strong potential in helping solar electricity become affordable.”

“At Tata, we are keen to support the company in achieving its vision. Such technologies have a potential to transform many lives for the better”, adds K.R.S. Jamwal, Executive Director, Tata Industries. “We admire the team and technology, based on a record setting efficiency of over 20% for CIGS from Empa, which we hope will be scaled up successfully. The funding will enable Flisom to purchase equipment and hire more experts to convert an innovative Swiss technology into an industrial reality.”

Flisom’s high performance products, processes and systems could lower the price of solar electricity thanks to low material usage, economic production technology, and reduced storage, transportation and installation costs.

Markets addressable by Flisom’s flexible solar module manufacturing technology include utility scale solar farms, building integrated photovoltaics (BIPV), building applied photovoltaics (BAPV), transportation, portable power and electronics.

The key is roll-to-roll manufacturing

The production technology is roll-to-roll manufacturing of flexible solar modules, involving deposition of CIGS thin films onto polymer foil. Founded as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology Zurich), Flisom has subsequently developed proprietary tools and processes for manufacturing solar modules.

After moving to Empa’s Dübendorf campus, Flisom has been collaborating with Empa’s Laboratory for Thin Films and Photovoltaics led by Ayodhya Nath Tiwari through various projects.

On 17 January 2013, Empa announced that its CIGS flexible solar cells achieved 20.4% photovoltaic conversion efficiency - a world record for CIGS technology that equals the record efficiency of polycrystalline Si wafer solar cells.

“Scale-up for large-area solar modules and adapting these complex innovative processes for industrial manufacturability is quite a challenge and requires close collaboration between research labs and industrial partner”, says Pierangelo Groening, head of the Department of Advanced Materials and Surfaces and member of the Board of Directors at Empa.

“Therefore, Empa and Flisom have signed a collaboration agreement on certain topics of flexible CIGS technology, and Empa has deputed Tiwari for a part-time involvement as senior strategic officer to support Flisom’s further development, a move that is instrumental to Empa’s long-term strategy to support early-stage companies with global market ambitions. This is a very special way of technology transfer - by way of sharing highly experienced staff. We expect Flisom to benefit greatly from Ayodhya Tiwari’s expert knowledge and experience. I see it as sort of a kick-start for the company’s new phase of development”, says Empa CEO, Gian-Luca Bona.

“The success also highlights, according to Bona, Empa’s strength in the field of renewable energy and, in particular, photovoltaics. We have several labs here at Empa devoted to the development of various innovative thin film technologies for solar energy generation”, he says.

“Along with the success of Flisom’s capital raise, we are very impressed by the high photovoltaic conversion efficiency attained by our scientific partners at Empa”, says Flisom interim CEO Kaelin.

Kaelin continued, “We look forward to benefitting from the insights of Empa to further raise the efficiency of flexible solar modules produced using Flisom’s industrial roll-to-roll vacuum deposition technology.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos